Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
about
FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repressionHuman CD8+ T cells do not require the polarization of lipid rafts for activation and proliferationGenetic engineering of T cells for adoptive immunotherapyAdoptive T cell therapy: Addressing challenges in cancer immunotherapyChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetA new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Linking form to function: Biophysical aspects of artificial antigen presenting cell designAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityNanoengineering approaches to the design of artificial antigen-presenting cellsMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cellsA novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cellsCreation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergensCancer immunotherapy via dendritic cellsHigh-resolution imaging of the immunological synapse and T-cell receptor microclustering through microfabricated substrates.Biopolymer implants enhance the efficacy of adoptive T-cell therapy.T-cell artificial focal triggering tools: linking surface interactions with cell response.High-Throughput Mechanobiology Screening Platform Using Micro- and NanotopographyHuman antigen-specific regulatory T cells generated by T cell receptor gene transfer.Dynamic regulation of functionally distinct virus-specific T cells.Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires.Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell helpToward synthetic biology with engineered T cells: a long journey just begun.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceT cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells.Use of tumour-responsive T cells as cancer treatment.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanomaCD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cellsTowards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignanciesHuman effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friendsAdoptive-cell-transfer therapy for the treatment of patients with cancer
P2860
Q24300168-EA055E89-4504-4A4D-B126-40CD5C1B7E02Q24538583-0779486B-E7A2-4C22-B0F6-A4B280936470Q24642718-02DC5409-86B2-4FCD-888E-0852951B6CB9Q24805804-D89108E0-71AF-4A57-A3A3-601C425A6209Q26799357-0B9972F2-4DCC-43B9-8E7D-A87E80C0C6DFQ26849476-6156727B-2EDC-49C8-A936-D72EE9E0E54DQ27002652-89433444-66FB-4BE1-BEF9-2C9599744A1EQ27004178-98ED13DF-9876-4B6E-80A5-A2C8A42169A4Q27012963-D5B03EF7-E487-470F-BBA9-F3CED87859B1Q27023634-67CF0E52-DA1F-4566-94D8-D8603027CD3EQ27309991-5129DDEA-68DF-4CF7-8244-3C517086F25CQ27345360-62036EC7-8349-4A23-9B0D-2FD396ED9371Q28829665-197284F5-52E3-44DC-9EDE-28CE15CED88BQ29615444-725993D8-19D2-4599-9326-7BB458D0B8E9Q30503844-E6EDBFB4-5159-4D51-BE42-8BB225C26FA5Q30614247-179B2403-7BBC-419E-9B20-D3DCF94AA346Q33416441-5261EFF4-B4F9-4CD1-80D2-1569BF93CBF7Q33598396-BEAD1460-6E0D-427F-94C7-6B61FD7F23EDQ33644234-C623EA99-51FD-476F-A7E8-027980AF3EDCQ33734502-42C76418-5807-4C6E-9E4E-64B40739E581Q33788105-F022CB18-0636-43F8-9F31-E437F137485AQ34080118-B3D4A961-47FB-4789-98AA-9E5476C0A3A3Q34083652-D29DCEDC-2F57-44A0-94FC-6B938B801CE7Q34139182-F8EC2423-C042-4CD1-8C1E-9DFEF23F5E99Q34141754-34180059-7350-4314-9FA8-A43E73CC344DQ34240817-02BC2C5F-1948-4ED7-B2A2-8F3F1AB319FEQ34245416-C817E69B-38B3-445B-85EC-4EECF8739880Q34284626-8AFA4BE1-1E9A-4600-83B1-8C74C198496FQ34285656-3242858E-0EB1-47E2-9158-B90F427C04B4Q34350259-1DB04D2D-4DFD-47EB-9ED6-A3AF5A00ECA3Q34352531-BDF5EF33-6B02-4C11-8404-52F9C891585BQ34391263-7E33E99A-488A-437B-9EAC-46D8EBEF2507Q34415738-3372E74E-41B5-41AD-8F0E-D4E79C77CC77Q34428078-654704DF-BA5A-4ACD-B76D-B7B1042AF411Q34517192-20767431-F456-4FB7-85D5-8622DC7BAC06Q34557953-17E18D3E-31C2-42D9-8116-F1228074F853Q34815702-EF126C4C-D31C-40D3-90FE-F1D1002BCB3DQ34987908-CFC6B9E5-3B8E-4D03-A07A-32F65566EF5BQ35001627-E2CA8541-05D1-42EE-AEBD-4DA76DC9B3F4Q35210008-44FA3629-0587-4FB3-BF10-BD19DF004C25
P2860
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Ex vivo expansion of polyclona ...... cell receptor, CD28 and 4-1BB.
@en
type
label
Ex vivo expansion of polyclona ...... cell receptor, CD28 and 4-1BB.
@en
prefLabel
Ex vivo expansion of polyclona ...... cell receptor, CD28 and 4-1BB.
@en
P2093
P2860
P356
P1433
P1476
Ex vivo expansion of polyclona ...... cell receptor, CD28 and 4-1BB.
@en
P2093
Anna K Thomas
Carl H June
David Allman
Debra G B Leonard
Kathakali Addya
Katia Schlienger
P2860
P2888
P304
P356
10.1038/NBT0202-143
P577
2002-02-01T00:00:00Z